Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma

BACKGROUND: Harnessing the immune system to purposely recognize and destroy tumors represents a significant breakthrough in clinical oncology. Non-synonymous mutations (neoantigenic peptides) were identified as powerful cancer targets. This knowledge can be exploited for further improvements of acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohsen, Mona O, Speiser, Daniel E, Michaux, Justine, Pak, HuiSong, Stevenson, Brian J, Vogel, Monique, Inchakalody, Varghese Philipose, de Brot, Simone, Dermime, Said, Coukos, Georges, Bassani-Sternberg, Michal, Bachmann, Martin F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753436/
https://www.ncbi.nlm.nih.gov/pubmed/35017147
http://dx.doi.org/10.1136/jitc-2021-002927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753436/
https://www.ncbi.nlm.nih.gov/pubmed/35017147
http://dx.doi.org/10.1136/jitc-2021-002927

Ejemplares similares